Galectin Therapeutics Inc.
GALT
$4.05
-$0.09-2.17%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 35.41% | 30.74% | 8.57% | 7.89% | -7.71% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.90% | -48.37% | -72.92% | -53.70% | -59.04% |
| Operating Income | 13.90% | 48.37% | 72.92% | 53.70% | 59.04% |
| Income Before Tax | -21.17% | 47.61% | 54.04% | 27.06% | 39.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -21.17% | 47.61% | 54.04% | 27.06% | 39.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.17% | 47.61% | 54.04% | 27.06% | 39.20% |
| EBIT | 13.90% | 48.37% | 72.92% | 53.70% | 59.04% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -16.57% | 49.34% | 55.19% | 28.99% | 40.19% |
| Normalized Basic EPS | -16.73% | 49.68% | 55.45% | 29.22% | 40.34% |
| EPS Diluted | -16.57% | 49.34% | 55.19% | 28.99% | 40.19% |
| Normalized Diluted EPS | -16.73% | 49.68% | 55.45% | 29.22% | 40.34% |
| Average Basic Shares Outstanding | 3.83% | 4.08% | 3.18% | 3.09% | 1.95% |
| Average Diluted Shares Outstanding | 3.83% | 4.08% | 3.18% | 3.09% | 1.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |